Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial.

Nature medicine·2026
Same author

CNS tumor type prevalence according to age group: An analysis of 21 000 cases confirmed by methylation profiling, with a focus on adolescents and young adults.

Neuro-oncology·2026
Same author

Intracranial mesenchymal tumor, FET::CREB fusion-positive: An integrative analysis of 81 cases.

Neuro-oncology·2026
Same author

Disseminated pediatric low-grade glioma and hydrocephalus: a multinational consortium analysis of incidence and mortality.

Journal of neurosurgery. Pediatrics·2026
Same author

Molecular and clinical stratification of astroblastomas: Three distinct fusion-defined groups informing risk-adapted treatment strategies.

Neuro-oncology·2025
Same author

Integrated clinical and molecular landscape of disseminated pediatric low-grade glioma.

Neuro-oncology·2025

Related Experiment Video

Updated: Jun 29, 2026

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
05:10

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Published on: October 3, 2010

Pediatric medulloblastoma.

Kazuhiro Sabet1, Hope Lovell2, Adriana Fonseca2

  • 1Department of Hematology and Oncology, Phoenix Children's Hospital, Phoenix, AZ, USA. ksabet@phoenixchildrens.com.

Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery
|June 27, 2026
PubMed
Summary

Medulloblastoma, a common childhood brain tumor, is now understood as diverse molecular subgroups. Research focuses on tailored treatments and biomarkers to improve survival while minimizing long-term side effects.

Keywords:
MedulloblastomaMolecular subgroupsPediatric brain tumorsRisk-adapted therapy

More Related Videos

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
06:32

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

Published on: September 1, 2010

Related Experiment Videos

Last Updated: Jun 29, 2026

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
05:10

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Published on: October 3, 2010

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
06:32

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

Published on: September 1, 2010

Area of Science:

  • Pediatric Oncology
  • Neuro-oncology
  • Molecular Biology

Background:

  • Medulloblastoma is the most frequent malignant pediatric brain tumor and a primary cause of cancer mortality in children.
  • It is now recognized as a heterogeneous group of diseases, classified into four main molecular subgroups (WNT, SHH, Group 3, and Group 4) and further defined by methylation subtypes.
  • These subgroups exhibit distinct genetic profiles, developmental origins, age distributions, metastatic patterns, and prognoses, influencing risk stratification and treatment decisions.

Purpose of the Study:

  • To review the fundamental biology of medulloblastoma.
  • To outline the historical progression of pediatric medulloblastoma therapies and clinical trials.
  • To describe current treatment strategies tailored to different age and risk categories and explore future research directions.

Main Methods:

  • Review of current literature on medulloblastoma biology, treatment evolution, and clinical trials.
  • Analysis of molecular subgroup classifications and their impact on clinical outcomes.
  • Evaluation of emerging biomarkers, such as cerebrospinal fluid (CSF) cell-free DNA (cfDNA), for monitoring residual disease.

Main Results:

  • Advances in surgery, radiotherapy, and chemotherapy have improved survival rates but often lead to significant long-term neurocognitive, endocrine, and psychosocial issues.
  • Current clinical trials aim to de-escalate therapy for low-risk medulloblastoma while intensifying or innovating treatments for high-risk subgroups.
  • Biomarkers like CSF cfDNA show promise for monitoring treatment response and guiding adaptive therapy.

Conclusions:

  • Medulloblastoma's molecular heterogeneity necessitates personalized treatment approaches.
  • Future research priorities include refining molecular risk stratification and developing biomarker-driven clinical trials.
  • The goal is to optimize treatment efficacy, reduce late effects, and improve outcomes for all pediatric medulloblastoma patients.